AstraZeneca completes acquisition of biotech company, EsoBiotec: Cambridge, UK Wednesday, May 21, 2025, 09:00 Hrs [IST] AstraZeneca announced the successful completion of the acqu ...

AstraZeneca AZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell ...

AstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

Initial clinical data from this trial are expected to be released in the second half of 2025,” said EsoBiotec Chief Scientific Officer Philippe Parone, PhD. “At ASGCT, we will present the ...

The acquisition, initially announced in March, sees AstraZeneca pay USD425 million up front, with an additional USD575 million in potential milestone payments, bringing the total consideration to up ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...

These large deals were Johnson & Johnson’s $14.6bn acquisition of Intra-Cellular Therapies, Novartis’ $3.1bn acquisition of Anthos Therapeutics, GSK’s $1.15bn buy of IDRx, and AstraZeneca’s $1bn ...